Skip to main content
. Author manuscript; available in PMC: 2022 Sep 7.
Published in final edited form as: Chem Soc Rev. 2021 Jul 22;50(17):9794–9816. doi: 10.1039/d1cs00017a

Table 2.

The biological properties, specificities and potencies of kinase inhibitors featured in this review.

Kinase Inhibitor target binding and kinase inhibition
(nM, cell-free unless otherwise noted)
UNC202511 MERTK Kd: 0.74
IC50 (in cell): 1 μM
dasatinib23,12 BCR-Abl Kd: Src 0.07; Abl 0.03
IC50 (μM): Src; 0.2, Abl 0.03, Lyn 0.6, Btk 1.5
BI253613 PLK1–3 IC50: PLK1 5.01;
PLK2 19.4; PLK3 9.37
nilotinib14 BCR-Abl IC50 (in cell): 20 – 60
spebrutinib15 Btk IC50: < 0.5
crizotinib16 ALK IC50 (in cells): 24
erlotinib17 EGFR IC50: 2
Ibrutinib7 Btk IC50: 68
gefitinib18 EGFR IC50 (in cells): 33
vemurafenib19 BRAFV600E IC50 (in cells): 64 – 110
afatinib20 EGFR, HER2 IC50 (in cell): 0.35 – 0.34 μM